Ikena Oncology (NASDAQ:IKNA – Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05, Zacks reports.
Ikena Oncology Stock Up 0.7 %
Shares of IKNA opened at $1.39 on Thursday. The company has a market capitalization of $67.08 million, a PE ratio of -1.13 and a beta of 0.49. Ikena Oncology has a 52-week low of $1.22 and a 52-week high of $1.94. The company has a 50-day simple moving average of $1.47 and a 200-day simple moving average of $1.61.
Analyst Ratings Changes
Separately, Wedbush reissued a “neutral” rating and set a $2.00 target price on shares of Ikena Oncology in a research note on Monday, December 23rd.
Ikena Oncology Company Profile
Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
Read More
- Five stocks we like better than Ikena Oncology
- How Investors Can Find the Best Cheap Dividend Stocks
- Gold Rally vs. Oil Surge: Where Investors Are Betting Next
- What Do S&P 500 Stocks Tell Investors About the Market?
- Intel Stock Surges on New CEO – The Real Story Runs Deeper
- 3 Stocks to Consider Buying in October
- Market Overreacts, But Guidewire’s Growth Story Remains Strong
Receive News & Ratings for Ikena Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ikena Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
